The Vaccine Adjuvant Compendium (VAC) was launched in 2021 by the NIAID Division of Allergy, Immunology, and Transplantation (DAIT) to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community.
Main Areas of Focus
- Display adjuvant characteristics or metadata defined through NIAID-supported adjuvant studies
- Help vaccine developers identify suitable adjuvants for various vaccine indications, including immune-mediated and infectious diseases
- Encourage the inclusion of adjuvant metadata generated by other research programs
Database of adjuvant characteristics or metadata defined through NIAID-supported adjuvant studies—Each adjuvant is assigned a unique ID number (vaccine ontology ID) that links the record to a corresponding entry in the Ontobee Vaccine ontology site. Authors are encouraged to cite this ID number in manuscripts on studies in which an adjuvant listed in VAC had been used.
VAC welcomes the inclusion of adjuvant metadata generated by other research programs.
More information about this resource is available at Vaccine Adjuvant Compendium
Access (Application Process)
Adjuvant records in VAC list the points of contact for each adjuvant to allow vaccine researchers to contact the IP holder directly. Adjuvant intellectual property (IP) holders are invited to deposit information about their adjuvants in VAC. Contact DAITAdjuvantGrp@niaid.nih.gov to establish a depositor-account.